Leyden Labs

Leyden Labs is pioneering a novel approach to respiratory virus protection by developing intranasal antibody sprays designed to provide immediate, broad-spectrum defense at the site of infection. The company's technology platform is built on two pillars: harnessing mucosal immunity for localized delivery and targeting conserved viral epitopes for enduring protection across virus families. Its lead program, PanFlu™, is in clinical development, with a pipeline aimed at creating self-administered products for both endemic and pandemic preparedness. Backed by a seasoned leadership team and strong investor syndicate, Leyden Labs is positioning itself as a key player in the next generation of antiviral prophylactics.

Platform for developing intranasal antibody sprays that harness mucosal immunity. It combines antibody engineering for stability and function in the nasal mucosa with a focus on targeting conserved viral epitopes to achieve broad, durable protection against respiratory virus families.

Leyden Labs competes in the broad-spectrum antiviral space, facing potential competition from other biotechs developing universal flu/coronavirus vaccines or monoclonal antibodies. Its primary differentiation is the localized, intranasal delivery for immediate prophylaxis, a niche with fewer established players but growing interest from large pharma.